In early 2021, as COVID-19 pandemic lockdowns and restrictions disrupted public life around the globe, MHRP faced the challenge of safely and ethically enrolling more than 100 participants in a new HIV vaccine adjuvant study in Kericho, Kenya.
MHRP and collaborators at two sites in Thailand are participating in the MAGI study, a NIAID-sponsored Phase 2 trial of a meningococcal Group B vaccine, Bexsero, in preventing gonococcal infection.
In 2021, MHRP, along with the Armed Forces Research Institute for Medical Sciences (AFRIMS) and the Department of Defense HIV/AIDS Prevention Program (DHAPP), received PEPFAR funding to develop a military-military partnership in the Philippines.
MHRP began enrolling participants in Homa Bay, Kenya, for a new prospective observational study of HIV and other sexually transmitted infections (STIs) called the Multinational Observational Cohort of HIV and Other Infections (MOCHI).
MHRP and collaborators recently launched a Phase 1 trial in Thailand that will evaluate two HIV vaccine candidates with and without the Army's novel ALFQ adjuvant to gain insight into late boosting strategies and the effects of fractional dosing.
